<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02449889</url>
  </required_header>
  <id_info>
    <org_study_id>000191</org_study_id>
    <nct_id>NCT02449889</nct_id>
  </id_info>
  <brief_title>A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation</brief_title>
  <acronym>FASHION</acronym>
  <official_title>A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Efficacy and Safety of Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) for Triggering of Final Follicular Maturation in Women Undergoing Controlled Ovarian Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is investigating the efficacy and safety of highly purified human chorionic
      gonadotropin (HP-hCG) and recombinant human chorionic gonadotropin (rhCG) for triggering of
      final follicular maturation in women undergoing controlled ovarian stimulation
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">March 1, 2018</completion_date>
  <primary_completion_date type="Actual">July 26, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>At oocyte retrieval (approximately 36 hours after hCG administration)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of metaphase II oocytes</measure>
    <time_frame>Prior to insemination (within 6 hours after oocyte retrieval)</time_frame>
    <description>Only applicable for insemination using intracytoplasmic sperm injection (ICSI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of fertilised (2 pronuclei (2PN)) oocytes</measure>
    <time_frame>1 day after oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive beta unit of human chorionic gonadotropin (βhCG) rate</measure>
    <time_frame>13-15 days after embryo transfer</time_frame>
    <description>Positive serum βhCG test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>5-6 weeks after embryo transfer</time_frame>
    <description>At least one gestational sac</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>From signing Informed Consent Form (ICF) until end of trial visit = maximum period 21 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of adverse events</measure>
    <time_frame>From signing ICF until end of trial visit = maximum period 21 weeks</time_frame>
    <description>Classified using a 3-point scale (mild, moderate, severe)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>HP-hCG IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>highly purified human chorionic gonadotropin, intramuscularly (IM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HP-hCG SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>highly purified human chorionic gonadotropin, subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhCG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>recombinant human chorionic gonadotropin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>highly purified human chorionic gonadotropin</intervention_name>
    <arm_group_label>HP-hCG IM</arm_group_label>
    <arm_group_label>HP-hCG SC</arm_group_label>
    <other_name>CHORAPUR</other_name>
    <other_name>BREVACTID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human chorionic gonadotropin</intervention_name>
    <arm_group_label>rhCG</arm_group_label>
    <other_name>OVIDREL</other_name>
    <other_name>OVITRELLE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-menopausal females between the ages of 18 and 39 years

          -  Documented history of infertility

          -  Body mass index (BMI) between 17.5 and 32.0 kg/m2

          -  Regular menstrual cycles

        Exclusion Criteria:

          -  Known endometriosis stage III and IV

          -  Known polycystic ovarian syndrome (PCOS)

          -  History of recurrent miscarriage

          -  History of more than three previous controlled ovarian stimulation cycles
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Ideia Fértil de Saúde Reproductive (there may be other sites in this country)</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2015</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

